Open AccessAntiplatelet agents’-ticagrelol and eptifibatide-safety in experimental colitis in mice
Author(s) -
Stanko Petrović,
Milijana Vasiljevska,
Slobodan Obradović,
Dino Tarabar,
Radoje Doder,
Ivana Majstorović,
Marijana Petrović,
Zvonko Magić,
Bojana Cikota,
Nenad Perišić,
Irina Brcerevic,
Nebojša Manojlović,
Nemanja Rančić
Publication year - 2020
Publication title -
the turkish journal of gastroenterology/the turkish journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.404
H-Index - 28
eISSN - 2148-5607
pISSN - 1300-4948
DOI - 10.5152/tjg.2020.19454
Subject(s) - medicine , eptifibatide , hematocrit , colitis , ticagrelor , platelet , gastroenterology , ulcerative colitis , inflammatory bowel disease , hemoglobin , spleen , pharmacology , aspirin , clopidogrel , percutaneous coronary intervention , disease , myocardial infarction
To evaluate the side effects of two antiplatelet agents - ticagrelor and eptifibatide - in mice with experimentally-induced inflammatory bowel disease.